Shuttle Pharmaceuticals to Present at ThinkEquity Conference

On October 28, 2024, Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) announced in an 8-K filing that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be presenting at the ThinkEquity Conference held at the Mandarin Oriental Hotel in New York City on October 30, 2024, at 8:30 am ET. The company will also be conducting one-on-one meetings with investors during the event.

Dr. Dritschilo’s presentation will provide updates on Shuttle Pharmaceuticals’ advancements towards clinical and scientific milestones for its Phase 2 clinical trial of Ropidoxuridine, a potential treatment for glioblastoma, a severe form of brain cancer. Furthermore, Dr. Dritschilo will outline the company’s plans for its subsidiary, Shuttle Diagnostics, Inc., including the development of predictive biomarkers for prostate cancer outcomes after radiation therapy, and the creation of a novel PSMA ligand for theranostic applications.

Interested parties can access the presentation through a webcast available at https://wsw.com/webcast/tep25/shph/1683504 or directly on the company’s website at https://shuttlepharma.com/investor-relations/. A replay of the presentation will also be accessible following the event.

In addition, Shuttle Pharmaceuticals updated its corporate presentation in preparation for the ThinkEquity Conference, posting it on their website at www.shuttlepharma.com. The investor presentation is provided as Exhibit 99.2 to the 8-K filing.

This 8-K filing includes forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the statements. These statements are made as of the date of the filing, and the company does not undertake any obligation to update or revise them, except as required by law.

Investors can find further information on Shuttle Pharmaceuticals and its performance in the company’s filings with the Securities and Exchange Commission, available on the SEC’s website at www.sec.gov.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Shuttle Pharmaceuticals’s 8K filing here.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .